Daiichi Sankyo Company, Limited (DSNKY)
OTCMKTS · Delayed Price · Currency is USD
23.72
+0.06 (0.25%)
Nov 24, 2025, 4:00 PM EST
Daiichi Sankyo Company Revenue
Daiichi Sankyo Company had revenue of 500.76B JPY in the quarter ending September 30, 2025, with 12.14% growth. This brings the company's revenue in the last twelve months to 1.98T, up 12.56% year-over-year. In the fiscal year ending March 31, 2025, Daiichi Sankyo Company had annual revenue of 1.89T with 17.77% growth.
Revenue (ttm)
1.98T JPY
Revenue Growth
+12.56%
P/S Ratio
3.27
Revenue / Employee
100.12M JPY
Employees
19,765
Market Cap
43.70B USD
Revenue Chart
* This company reports financials in JPY.
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Mar 31, 2025 | 1.89T | 284.57B | 17.77% |
| Mar 31, 2024 | 1.60T | 323.21B | 25.28% |
| Mar 31, 2023 | 1.28T | 233.59B | 22.36% |
| Mar 31, 2022 | 1.04T | 82.38B | 8.56% |
| Mar 31, 2021 | 962.52B | -19.28B | -1.96% |
| Mar 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| American Oncology Network | 1.76B |
| Veradigm | 588.02M |
| Glass House Brands | 196.17M |
| Global Cord Blood | 196.10M |
| Elite Pharmaceuticals | 122.89M |
| Mid-Atlantic Home Health Network | 27.00M |
| Silence Therapeutics | 25.83M |
| Tian'an Technology Group | 2.12M |
Daiichi Sankyo Company News
- 12 days ago - Daiichi Sankyo partnering with General Proximity on oncology targets - Seeking Alpha
- 12 days ago - General Proximity Announces Multi-Target Collaboration with Daiichi Sankyo to Discover and Advance Novel Oncology Therapeutics Using OmniTAC™ Platform - PRNewsWire
- 14 days ago - DS3610 Enters Clinical Development in Patients with Advanced Solid Tumors as First STING Agonist ADC in Industry-Leading ADC Portfolio of Daiichi Sankyo - Business Wire
- 19 days ago - Daiichi Sankyo Company, Limited (DSNKY) Q2 FY2025 Earnings Call Transcript - Seeking Alpha
- 22 days ago - Q2 2026 Daiichi Sankyo Co Ltd Earnings Presentation Transcript - GuruFocus
- 24 days ago - Daiichi Sankyo (DSKYF) Reports Strong 1H Financial Results - GuruFocus
- 25 days ago - Daiichi Sankyo GAAP EPS of ¥70.52, revenue of ¥975.35B; updates FY outlook - Seeking Alpha
- 25 days ago - Daiichi Sankyo Company, Limited 2026 Q2 - Results - Earnings Call Presentation - Seeking Alpha